Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ch10D7 + MMAE
- Development stage
- Unknown
- Lead developer
- The University of Queensland
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ch10D7 + MMAE is an antibody-drug conjugate (ADC) combining the chimeric anti-CDCP1 monoclonal antibody ch10D7 with monomethyl auristatin E (MMAE), a potent microtubule-disrupting cytotoxin. The antibody targets CUB domain-containing protein 1 (CDCP1), which is overexpressed in several solid tumors (including pancreatic, colorectal, ovarian, triple-negative breast, HER2+ breast, and lung cancers) and internalizes upon binding, delivering MMAE to cancer cells to induce cytotoxicity. Preclinical studies demonstrate robust anti-tumor efficacy in various xenograft models, with high specificity for CDCP1-expressing cells and limited effect on normal tissues. ch10D7 + MMAE is being developed mainly for cancer therapy and is not yet approved for clinical use[2][3][4][5][6].
- Other names
- ch10D7-MMAEch-10D7-MMAEch 10D7-MMAE10D7-MMAE
02
Targets
TUBB (Tubulin (alpha and beta subunits))CDCP1 (CUB domain-containing protein 1)
Beyond the preview
Go deeper on ch10D7 + MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ch10D7 + MMAE.